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Soft tissue sarcoma is a rare disease. We began a prospective database for in-patients treated on the surgical
service at Memorial Sloan-Kettering in 1982. We now celebrate 30 years of this database which has been
reviewed and cataloged constantly on a weekly basis. We approach 10,000 treated patients. The study of
this heterogeneous group of diverse pathology rising in the soft tissue has been fascinating. We have learned
about demographics, prevalence, incidence, and have recognized the value of such databases in describing
not just outcome but biology. Site is an important determinant of outcome and illustrates the complexities of
including all sites in any staging system. For example, local recurrence in the extremity, while associatedwith
a decrease in survival, is clearly not causative. Conversely, retroperitoneal sarcoma, particularly liposarcoma,
is a common locally recurring disease with local progression often the cause of disease-speciﬁc mortality.
Genetic predispositions have been deﬁned. Radiation therapy and lymphedema, both alone and in
combination, predispose to the development of sarcoma. These observations have important relevance as
we increasingly utilize radiation therapy to minimize local recurrence in early stage breast cancer and
ductal carcinoma in situ. It is clear that outcome is histology speciﬁc and wide variations in outcome,
depending on the underlying histological types and subtypes, are evident. We have established very clearly
that limb preservation as opposed to amputation is equally efﬁcacious and does not diminish survival.
Radiation therapy can limit local recurrence but must be balanced against side effects. Unfortunately, the
majority of chemotherapeutic regimens have had minimal beneﬁt.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
It is a pleasure to be present to recognize the major contributions of
Professor Renzo Dionigi. We began our commonality of interests in
the late 1970s at which time we were both interested in nutritional
support particularly as it relates to malignant disease. 1–3
Subsequent interest diverged somewhat as Professor Dionigi made
signiﬁcant contributions to the immunology of infection following
his time with Dr. Wesley Alexander. However, it is of interest to note
that in the ﬁrst decade of the 21st Century, we remain with similar
interest, for example in themanagement of the inferior vena cavawith
malignant disease and the role of blood transfusion in outcome after
major hepatic or pancreatic surgery. 4–7 It is a pleasure to recognize
Professor Dionigi and his major contributions here in Varese.
I have elected to speak about a subject that has fascinated me for
the last 40 years. This year we will celebrate the 30th anniversary
of the initiation of the soft tissue sarcoma database at Memorial
Sloan-Kettering Cancer Center (MSKCC). This database, which I began
shortly after arriving at MSKCC, is an in-patient database recording
information on all of the patients admitted for surgical care. It
is prospective, reviewed on a weekly basis and has provided a
great source of information about the management of this complex
group of diseases. We have entered over 9,000 patients (Fig. 1)
with a distribution that is well known. Approximately 40% are in
Fig. 1. Soft tissue sarcoma by site. MSKCC July 1, 1982 through June 30, 2011. n = 9040.
Retro-IA, retroperitoneal–intraabdominal.
the extremities and the rest distributed throughout the body. We
now know a great deal about the genetic predisposition, tumors
occurring in the background of neuroﬁbromatosis, in associationwith
Li Fraumeni syndromeattributed tomutations in the p53 gene and the
interesting association of the desmoid tumorwithGardner Syndrome.
Gardner is certainly of some historical interest being born in 1909 and
dying in 1989. However, he reported his syndrome at the age of 80
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Fig. 2. Histologic distribution of soft tissue sarcoma. MSKCC July 1, 1982 through
June 30, 2011. n =9040. GIST, gastrointestinal stromal tumor; MFH, malignant ﬁbrous
histiocytoma, MPNST, malignant peripheral neural stromal tumor.
in a journal that is no longer published! Evidence that there are still
opportunities for us senior citizens to contribute!
We know that radiation exposure is an etiological agent in the
development of soft tissue sarcoma and occurs in those diseases
commonly treated with radiation, such as lymphoma, breast, cervical
and prostate cancer. These radiation-induced sarcomas are often
very difﬁcult to deal with and the dominant histological type is a
myxoﬁbrosarcoma. It is important to recognize that the occurrence of
soft tissue sarcoma as a consequence of radiation, while rare, is often
underappreciated. An analysis of 16,705 patients from the Institute
Curie followed with and without radiation, 8 showed recurrence is at
least ten-fold in those receiving radiation therapy, and the cumulative
risk 5 in 1,000 patients at the end of 15 years. This is important as
we consider the widespread utilization of radiation therapy in the
treatment of ductal carcinoma in situ (DCIS), particularly in North
America. One can only anticipate a further increase in this lethal
disease given the marked increase in the prevalence with which DCIS
is reported. For example, in 1975 the incidence was 1.87 per 100,000
and in 2004 the incidence was 32.5 per 100,000. 9
It is also important to recognize lymphedemaas a background agent
in the development of angiosarcoma, ﬁrst reported from Memorial
Sloan-Kettering in the ﬁrst edition of Cancer by Drs. Stewart and
Treves. 10 This lethal multifocal lesion can be anticipated to occur
much less frequently now that extended operations for breast cancer
accompanied by postoperative radiation are less and less entertained.
Nevertheless, lymphedema remains even in the era of sentinel
lymph node biopsy but is certainly less than it was at the time
of extensive lymph node dissection and postoperative radiation.
Lymphedema is seen in parasitic lymphatic obstruction, and this
too can be the source of malignant degeneration to angiosarcoma.
Chemical toxins, now used infrequently, have been incriminated in
the etiology of soft tissue sarcoma but are a much less common event
in current practice.
We have learned a great deal about the histological subtypes of
soft tissue sarcomas (Fig. 2). This subject is in evolution as the entity
previously considered malignant ﬁbrous histiocytoma is considered
pleomorphic sarcoma, or more commonly a variant of myxo-
ﬁbrosarcoma. Noted purely by the body site, the histological subtype
varies with liposarcomamost commonly seen in the retroperitoneum
and themajority of visceral sarcomas now considered gastrointestinal
stromal tumors. Individual histological subtypes within designations
showed marked variation in behavior. An excellent example is the
differences seen in the subtypes of liposarcoma (Fig. 2). 11 Disease-
speciﬁc survival can vary from 90% alive to 35% alive at ten years,
purely based on the nature of the underlying histological subtype.
This has major implications for clinical trials as stratiﬁcation is
often not considered. An early recognition of the importance of
histological grade allowed great prognostication based on this simple,
albeit subjective, interpretation under the microscope. Nevertheless,
in rare subtypes where prediction of outcome may be difﬁcult,
such observations became important. Approximately two-thirds of
patients will have a high-grade lesion and one-third of patients will
have a low-grade lesion, and their outcome is remarkably reﬂected
with the high-grade lesions having approximately 50% 10-year risk
of death from disease whereas the low-grade lesions approximate
10–15%.
Dr. James Ewing, the Clinical Director at Memorial Sloan-Kettering,
was on the cover of Time Magazine in January of 1931, and ﬁrst
described the small blue round cell tumor that bears his name.
We now know that the Ewing’s gene family consists of multiple
different genetic aberrations which allow us to characterize tumors
with a genetic signature. An excellent example of this is synovial
cell sarcoma, which historically was mislabeled because of its
assumed association with peripheral joints but is now deﬁned by the
presence or absence of an SYT–SSX fusion gene. This has important
implications because with a genetic signature we now make the
diagnosis of tumors in sites not commonly anticipated. For example,
in synovial sarcoma the diagnosis has been made in prostate, lung,
heart and tongue among others, based on this genetic signature.
The potential for these genetic fusion genes being targets for future
therapy is an important one and requires future evaluation.
As a consequence of our very signiﬁcant experience, we have been
able to develop prognostic predictors of outcome. 12 It is important to
emphasize that outcomes vary and predictors of outcome vary even
more depending on the outcome variable considered. For example,
predictors of local recurrencewill differ from the predictors of distant
recurrence and indeed of distant disease-speciﬁc survival (Table 1).
Lymph node metastases are rare in soft tissue sarcoma, occurring
in <3% of all patients. They are more commonly seen in the
epithelial subtypes but are very rarely seen in entities such as
liposarcoma. 13 There has been some debate as to the relevance of
lymphnodemetastasis, but it is clear that in a very small subsetwhere
lymph node metastases alone are a solitary source of metastatic
disease, lymph node dissection can, in selective patients, be curative.
We have progressed signiﬁcantly from staging and simple entities
of prognostication, to the development of predictive nomograms,
which are graphical representations of statistical models deﬁning
the probability of outcome based on patient-speciﬁc entities or
following speciﬁc treatment. These nomograms require large datasets
and signiﬁcant events both negative and positive. Combined with
adequate length of follow up they can be powerful tools for predictive
outcomes for individual patients. Nevertheless, they require deﬁned
populations, deﬁned outcomes, known risk factors and require once
established, validation in other datasets. This we have utilized for
validation. 14,15 Perhaps most important for this audience validation
within an Italian dataset! 16 It is important to emphasize that
nomograms can be site or histology speciﬁc, they can be time altered,
or they can be recurrence altered. They have the potential to allow the
addition of biological variables and indeedmay be tools for predicting
the effects of treatment. We have further explored such association
with the use of Bayesian Belief Networks.
The diagnosis and treatment of soft tissue sarcoma has certainly
improved. No longer do we require major incisional biopsies with ac-
companying morbidity, but in the vast majority of patients diagnosis
can be made histologically with a single TruCut core biopsy. Many
believe that with the advent of immunohistochemistry, accurate
diagnosis can be made on cytology alone. Given the importance of
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Table 1
Prognostic factors in soft tissue sarcomaa
Local recurrence Post metastasis survival Distant recurrence Disease-speciﬁc survival
Local recurrence at presentation Size >10 cm High grade High grade
Positive margins Size >5 cm Size >10 cm
Fibrosarcoma Size >10 cm Deep location
Age >50 Deep location Positive margins
Local recurrence at presentation Local recurrence at presentation
Lower extremity site
a Adapted from: Pisters P, Leung D, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the
extremity. J Clin Oncol 1996;14(5):1679–89.
molecular diagnosis, a core biopsy would appear to be the standard
approach.
In terms of treatment, we have gone from an era where amputation
was the standard and the only procedure, to limb-sparing procedures
in the great majority (>95%) of patients with extremity lesions. It is
often accompanied by radiation therapywhich limits local recurrence
but in randomized trials does not change survival. 17 Local recurrence
occurs in primary extremity lesions approximately 15% of the time.
In those patients with isolated recurrence, they can be rescued by
further procedures and the likelihood of success is determined by
rapidity of recurrence and the size of recurrence at the time of
diagnosis. For patients with a high-grade recurrence >5 cm occurring
within 16 months, 4-year disease-speciﬁc survival is 18%, whereas
patients who develop a small low-grade recurrence >16 months can
have a 4-year disease-speciﬁc survival in excess of 80%. 18 Adjuvant
chemotherapy, which has been shown to be effective in pediatric
sarcomas, has been widely tested but with very limited value in adult
soft tissue sarcoma.
Once again, it is a great pleasure to be able to present this brief lecture
on a subject of interest to me to honor the many achievements of
Professor Renzo Dionigi.
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